Literature DB >> 35356801

Double Empirical Bayes Testing.

Wesley Tansey1, Yixin Wang2, Raul Rabadan3, David M Blei2,4.   

Abstract

Analyzing data from large-scale, multi-experiment studies requires scientists to both analyze each experiment and to assess the results as a whole. In this article, we develop double empirical Bayes testing (DEBT), an empirical Bayes method for analyzing multi-experiment studies when many covariates are gathered per experiment. DEBT is a two-stage method: in the first stage, it reports which experiments yielded significant outcomes; in the second stage, it hypothesizes which covariates drive the experimental significance. In both of its stages, DEBT builds on Efron (2008), which lays out an elegant empirical Bayes approach to testing. DEBT enhances this framework by learning a series of black box predictive models to boost power and control the false discovery rate (FDR). In Stage 1, it uses a deep neural network prior to report which experiments yielded significant outcomes. In Stage 2, it uses an empirical Bayes version of the knockoff filter (Candes et al., 2018) to select covariates that have significant predictive power of Stage-1 significance. In both simulated and real data, DEBT increases the proportion of discovered significant outcomes and selects more features when signals are weak. In a real study of cancer cell lines, DEBT selects a robust set of biologically-plausible genomic drivers of drug sensitivity and resistance in cancer.

Entities:  

Keywords:  cancer drug studies; empirical Bayes; knockoffs; multiple testing; two-groups model

Year:  2020        PMID: 35356801      PMCID: PMC8963776          DOI: 10.1111/insr.12430

Source DB:  PubMed          Journal:  Int Stat Rev        ISSN: 0306-7734            Impact factor:   2.217


  11 in total

1.  False discovery rate regression: an application to neural synchrony detection in primary visual cortex.

Authors:  James G Scott; Ryan C Kelly; Matthew A Smith; Pengcheng Zhou; Robert E Kass
Journal:  J Am Stat Assoc       Date:  2015       Impact factor: 5.033

2.  Inactivation of the p53 pathway in retinoblastoma.

Authors:  Nikia A Laurie; Stacy L Donovan; Chie-Schin Shih; Jiakun Zhang; Nicholas Mills; Christine Fuller; Amina Teunisse; Suzanne Lam; Yolande Ramos; Adithi Mohan; Dianna Johnson; Matthew Wilson; Carlos Rodriguez-Galindo; Micaela Quarto; Sarah Francoz; Susan M Mendrysa; R Kiplin Guy; Jean-Christophe Marine; Aart G Jochemsen; Michael A Dyer
Journal:  Nature       Date:  2006-11-02       Impact factor: 49.962

3.  FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.

Authors:  Jian-Hua Mao; Il-Jin Kim; Di Wu; Joan Climent; Hio Chung Kang; Reyno DelRosario; Allan Balmain
Journal:  Science       Date:  2008-09-12       Impact factor: 47.728

4.  Systematic identification of genomic markers of drug sensitivity in cancer cells.

Authors:  Mathew J Garnett; Elena J Edelman; Sonja J Heidorn; Chris D Greenman; Anahita Dastur; King Wai Lau; Patricia Greninger; I Richard Thompson; Xi Luo; Jorge Soares; Qingsong Liu; Francesco Iorio; Didier Surdez; Li Chen; Randy J Milano; Graham R Bignell; Ah T Tam; Helen Davies; Jesse A Stevenson; Syd Barthorpe; Stephen R Lutz; Fiona Kogera; Karl Lawrence; Anne McLaren-Douglas; Xeni Mitropoulos; Tatiana Mironenko; Helen Thi; Laura Richardson; Wenjun Zhou; Frances Jewitt; Tinghu Zhang; Patrick O'Brien; Jessica L Boisvert; Stacey Price; Wooyoung Hur; Wanjuan Yang; Xianming Deng; Adam Butler; Hwan Geun Choi; Jae Won Chang; Jose Baselga; Ivan Stamenkovic; Jeffrey A Engelman; Sreenath V Sharma; Olivier Delattre; Julio Saez-Rodriguez; Nathanael S Gray; Jeffrey Settleman; P Andrew Futreal; Daniel A Haber; Michael R Stratton; Sridhar Ramaswamy; Ultan McDermott; Cyril H Benes
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

5.  MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.

Authors:  R F H Walter; F D Mairinger; S Ting; C Vollbrecht; T Mairinger; D Theegarten; D C Christoph; K W Schmid; J Wohlschlaeger
Journal:  Br J Cancer       Date:  2015-02-10       Impact factor: 7.640

6.  The pharmacodynamics of the p53-Mdm2 targeting drug Nutlin: the role of gene-switching noise.

Authors:  Krzysztof Puszynski; Alberto Gandolfi; Alberto d'Onofrio
Journal:  PLoS Comput Biol       Date:  2014-12-11       Impact factor: 4.475

7.  Identification and correction of spatial bias are essential for obtaining quality data in high-throughput screening technologies.

Authors:  Bogdan Mazoure; Robert Nadon; Vladimir Makarenkov
Journal:  Sci Rep       Date:  2017-09-20       Impact factor: 4.379

8.  Causal inference in genetic trio studies.

Authors:  Stephen Bates; Matteo Sesia; Chiara Sabatti; Emmanuel Candès
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-18       Impact factor: 11.205

9.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.

Authors:  Wanjuan Yang; Jorge Soares; Patricia Greninger; Elena J Edelman; Howard Lightfoot; Simon Forbes; Nidhi Bindal; Dave Beare; James A Smith; I Richard Thompson; Sridhar Ramaswamy; P Andrew Futreal; Daniel A Haber; Michael R Stratton; Cyril Benes; Ultan McDermott; Mathew J Garnett
Journal:  Nucleic Acids Res       Date:  2012-11-23       Impact factor: 16.971

10.  The tumour suppressor CYLD regulates the p53 DNA damage response.

Authors:  Vanesa Fernández-Majada; Patrick-Simon Welz; Maria A Ermolaeva; Michael Schell; Alexander Adam; Felix Dietlein; David Komander; Reinhard Büttner; Roman K Thomas; Björn Schumacher; Manolis Pasparakis
Journal:  Nat Commun       Date:  2016-08-26       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.